ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study
29.7.2026 09:00:00 CEST | Business Wire | Press release
Levels of 17 analytes usually found in cigarette smoke tested in aerosols from ELFBAR ELFA pods 10 harmful constituents below detectable levels, with formaldehyde and acetaldehyde up to 99.9%* lower than those in cigarette smoke Metals detected well below safety thresholds Complete switching to ELFA significantly reduces or brings to zero adult users’ exposure to harmful constituents
Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal.
Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon.
Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or even eliminate, their exposure to multiple harmful constituents compared with consuming combustible cigarettes.
“This study adds to the growing scientific evidence supporting the effective role vaping products play in reducing, or even eliminating, exposure to harmful chemical substances for adult smokers,” said an ELFBAR spokesperson.
“Providing adult users with quality cessation alternatives has been at the heart of ELFBAR since the brand’s inception, and we remain committed to elevating product safety standards through continuous innovation and practice,” the spokesperson commented.
Ten of 17 analytes undetected or below quantifiable levels
Ten out of the 17 analytes were undetectable or below quantifiable levels across all tested ELFA pods in these four flavors, including carbon monoxide (CO), tobacco-specific nitrosamines NNK and NNN, acrolein, benzo[a]pyrene, 1,3-butadiene, and benzene, among others.
The undetectable or non-quantifiable levels of these chemicals commonly found in smoke suggest a substantial reduction in user exposure to harmful constituents.
Metals well below safety thresholds
Metal emissions in ELFA aerosols, with concentrations measured in micrograms per 100 puffs are also evaluated.
Cadmium and arsenic are not detected in aerosols from any of the tested ELFA pods. Chromium, aluminum, iron, and tin are partly found at low traceable levels in certain pods.
In these tests, estimated exposure levels for detectable metals, including lead, chromium, nickel, aluminum, iron, and tin, were well below the safety thresholds by the US Pharmacopeia and the US National Institute for Occupational Safety and Health.
Overall, the metal exposure from ELFA aerosols was minimal and therefore is not considered to pose a toxicological concern under the conditions of evaluation.
Up to 99.9%* lower levels of carbonyls
Formaldehyde and acetaldehyde, two well-recognized carcinogens, were approximately 99.6% to 99.9% lower in ELFA aerosols than in cigarette smoke. Although both compounds were detected across the four ELFA pods, they were present at very low levels, and well below the safety thresholds.
“Many adult smokers misperceive vaping as being as harmful as, or more harmful than smoking, and such misconception continues to raise a barrier to cessation. At ELFBAR, we believe transparent, science-based research is essential to helping adult users make informed choices during the whole process of their transition away from combustible tobacco,” the spokesperson added.
ELFA features a next-generation iron-chromium-aluminum alloy mesh heating coil, a key component that vaporizes the e-liquid. This part reduces exposure to harmful constituents compared with cotton and ceramic coil-equipped devices, with much lower risk than cigarette smoke.
* Page 3: For the remaining two non-metal analytes (formaldehyde and acetaldehyde), both of which are also found in the WHO TobReg proposal, formaldehyde was reduced by between 99.6% and 99.9%, and acetaldehyde was reduced by between 99.7% and 99.9%, depending on the flavor being assessed.
About ELFBAR
ELFBAR is a pioneer in the global vaping industry. Since its inception in 2018, it has been providing a distinct and diverse vaping experience with innovation at its core.
ELFBAR stays committed to youth access prevention and sustainable growth as a leading brand favoured and used by tens of millions of adult smokers and ex-smokers worldwide as an alternative to smoking.
For more information, please visit elfbar.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260729533598/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom